$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Recently, advances have been made toward the development and production of in vitro human skin models for the analysis of the toxicity of cosmetic and pharmaceutical products1. Researchers in pharmaceutical and skin care industries have been using animals, mice being the most common, to test their products2,3,4,5. However, testing products on animals is not always predictive of the response in humans, which frequently leads to drug failure or adverse effects in humans and consequently to economic losses5,6. The UK was the first country that prohibited the use of animals for cosmetic testing in 1998. Later, in 2013, the EU banned the testing and approbation of cosmetics in animals (EU Cosmetics Regulation No. 1223/2009)7.
This prohibition is also being considered by other countries such as in 'The Humane Cosmetics Act' in the USA8. In addition to ethical concerns, the anatomical differences between animal and human skin make animal testing time-consuming, expensive, and often ineffective. Furthermore, the global in vitro toxicology testing market size is expected to reach USD 26.98 billion by 20259. For these reasons, there is a need to develop new methods and alternatives for those in vitro studies, such as bioengineered human skin models, that enable testing for safety and toxic effects of cosmetics and drugs without the use of animals.
There are two different kinds of commercially available, in vitro, human skin models. The first type consists of stratified epidermal equivalents containing multiple layers of differentiating keratinocytes that are seeded on different materials. Some of them have been approved by the Organization for Economic Co-operation and Development (OECD) and validated by the (European Centre for the Validation of Alternative Methods (ECVAM) for skin corrosion and irritation testing, such as EpiDerm or SkinEthic10,11,12. The second type are full-skin equivalents with a layer of differentiating human keratinocytes seeded on a three-dimensional (3D) scaffold that contains fibroblasts, such as T-Skin and EpiDerm-FT. However, these models are cultured under static conditions, which makes them unable to accurately represent human physiological conditions.
Recent interest has focused on generating in vitro 3D skin models in cell culture-insert (CCI) formats with dynamic perfusion13,14,15,16,17,18,19. However, these systems cannot be considered stricto sensu as microfluidic skin-on-chips as per their classical definition in the field. Ingber's definition for organs-on-a-chip states that the organ must be placed inside the microfluidic channels, which is a condition that only a few devices fulfil20,21. Skin-on-chips have so far modelled mostly simple epithelia as single-cell layers and/or dermal cell layers separated by a porous membrane22,23. Although there have been some advances modeling skin in microfluidic systems16,24, there is currently no literature showing an organ-on-a-chip system that fits Ingber's definition, capable of producing a multilayered skin in situ and including both epithelial and stromal components.
In this work, a new, cost-effective, robust, vinyl-based microfluidic platform for skin-on-a-chip applications is presented. This platform was produced by micro-machining, which provides more simplicity in the fabrication process, as well as increased flexibility and versatility in the layout of the device, overcoming some of the limitations of PDMS25. A way to introduce a simplified skin construct through a parallel flow controlled with syringe pumps was also designed. Parallel flow allows two fluids with very different viscosities (a buffer and fibrin pre-gel in this case) to be perfused through a channel without mixing with each other. As a proof of concept, a dermo-epidermal construct containing fibroblasts embedded in a fibrin matrix mimicking the dermis was introduced in the device, on top of which a monolayer of keratinocytes was loaded to emulate the undifferentiated epidermis. The dermal compartment height can be modulated by modifying the flow rates. The main novelty of this work, compared to previously described models22,26,27,28,29, is the development of a 3D construct inside a microchamber by means of microfluidics. Although this article presents a simplified undifferentiated skin, the long-term goal is to generate and characterize a fully differentiated skin construct to demonstrate its viability and functionality for drug and cosmetic testing purposes.